Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 2 for:    Cat-Scratch Disease
Previous Study | Return to List | Next Study

Intra-nodal Injection of Gentamicin for the Treatment of Suppurated Cat Scratch Disease's Lymphadenitis (BIGG)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03132116
Recruitment Status : Recruiting
First Posted : April 27, 2017
Last Update Posted : August 27, 2021
Sponsor:
Information provided by (Responsible Party):
University Hospital, Toulouse

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
To compare effect of intra-nodal injection of gentamicin versus placebo on the outcome at 28 days of suppurated cat scratch disease's (CSD) lymphadenitis treated by oral azithromycin.

Condition or disease Intervention/treatment Phase
Cat-Scratch Disease Drug: gentamicin Drug: placebo Phase 3

Detailed Description:
Double blind controlled study versus placebo. Patients with suppurated CSD's lymphadenitis will receive immediately after the pus aspiration (performed for a diagnostic purpose) an intra-nodal injection of gentamicin or of placebo (NaCl 0,9%) and be treated with oral azithromycin for 5 days.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Intra-nodal Injection of Gentamicin for the Treatment of Suppurated Cat Scratch Disease's Lymphadenitis: A Randomized Controlled Study
Actual Study Start Date : May 31, 2017
Estimated Primary Completion Date : May 2022
Estimated Study Completion Date : May 2022

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Gentamicin
intra-nodal injection of gentamicin
 Drug: gentamicin

After inclusion in the study, patient will be randomized. According to randomization, patient will receive an intra-nodal injection of gentamicin .

As well, azithromycin will be prescribed for all patients for 5 days. Patients will be followed-up each week until week 4 (Day 28).
Placebo Comparator: Placebo
intra-nodal injection of placebo
 Drug: placebo

After inclusion in the study, patient will be randomized. According to randomization, patient will receive an intra-nodal injection of placebo.

As well, azithromycin will be prescribed for all patients for 5 days. Patients will be followed-up each week until week 4 (Day 28).

Other Name: NaCl


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Frequency at day 28 of CSD's adenitis favorable outcome [ Time Frame: Day 28 ]
    Adenitis favorable outcome characterized as : Reduction of the volume of the adenitis, Without requirement of supplementary needle aspirations after day 7's visit, And without requirement of a surgical excision or incision of the adenitis.


Secondary Outcome Measures :
  1. Reduction of the adenitis [ Time Frame: from Day 0 to Day 28 ]
    Percentage of volume reduction of the adenitis

  2. Evaluation of the pain related to the adenitis [ Time Frame: between Day 0, Day 7 and Day 28 ]
    Percentage of reduction of the pain related to the adenitis

  3. Fistulization of the adenitis [ Time Frame: Day 7 and day 28 ]
    Number of patients with persisting cutaneous fistulization of the adenitis

  4. Surgical action [ Time Frame: Day 28 ]
    Number of patients requiring surgical excision or incision of the adenitis

  5. Protein C reactive [ Time Frame: Day 0 and day 7 ]
    Percentage of decrease of serum Protein C reactive

  6. Antibiotic resistance [ Time Frame: Day 28 ]
    Genotypic profile of resistance to macrolides and aminoglycosides

  7. Safety of treatment [ Time Frame: Day 7 and day 28 ]
    Incidence of Treatment-Emergent Events linked to the study treatment


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Informed consent

  • Suppurated CSD's adenitis:

    • Suppurated form of adenitis confirmed by echography
    • Serology positive for Immunoglobulin G and/or Immunoglobulin M against B. henselae

Exclusion Criteria:

  • Suppurated adenitis non related to CSD
  • Non-suppurated CSD's adenitis
  • Suppurated CSD's adenitis already fistulized
  • Suspected visceral B. henselae infection (neurologic or ophthalmic symptoms, hepato-splenic or valvular involvement confirmed by echography)
  • Immunodepression (except diabetes)
  • Pregnancy
  • Contraindication to pus aspiration from lymphadenitis (history of bleeding or patient taking curative anticoagulation therapy or platelet count < 50.000/mm3)
  • Contraindication to azithromycin (history of QT interval prolongation, history of liver toxicity of hypersensitivity to macrolides or treatment with ergotamine, dihydroergotamine, bepridil, cisapride, pimozide, mizolastine or colchicine) or to aminoglycosides (myasthenia, history of hypersensitivity to aminoglycosides).
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03132116


Contacts
Layout table for location contacts
Contact: Guillaume MARTIN-BLONDEL, MD, PhD +33 (0) 5 61 77 96 99 martin-blondel.g@chu-toulouse.fr
Contact: Alexa DEBARD, MD +33 (0) 5 61 77 95 86 debard.a@chu-toulouse.fr

Locations
Show Show 21 study locations
Sponsors and Collaborators
University Hospital, Toulouse
Investigators
Layout table for investigator information
Principal Investigator: Guillaume MARTIN-BLONDEL, MD, PhD University Hospital of Toulouse, Infectious & Tropical Diseases department
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: University Hospital, Toulouse
ClinicalTrials.gov Identifier: NCT03132116    
Other Study ID Numbers: 15 7834 08
First Posted: April 27, 2017    Key Record Dates
Last Update Posted: August 27, 2021
Last Verified: August 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University Hospital, Toulouse:
Cat Scratch Disease's lymphadenitis
Infectious Diseases
Additional relevant MeSH terms:
Layout table for MeSH terms
Cat-Scratch Disease
Lymphatic Diseases
Lymphadenitis
Bacterial Infections and Mycoses
Infections
Bartonella Infections
Bartonellaceae Infections
Gram-Negative Bacterial Infections
 Bacterial Infections
Gentamicins
Anti-Bacterial Agents
Anti-Infective Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action